Rein Therapeutics Presents Inhaled LTI-03 Phase 1b Dose-Escalation Poster at ERS Congress Following Nature Communications Publication; First Synthetic Caveolin-1 Peptide for IPF Reduces IL-11 and TSLP
Rein Therapeutics (NASDAQ: RNTX) presented Tuesday September 8, 2026 (poster PA6217, 12:30-2:00 p.m. CEST) at the European Respiratory Society Congress in Barcelona the Phase 1b randomized double-blind placebo-controlled dose-escalation study of inhaled LTI-03 in patients with idiopathic pulmonary fibrosis. LTI-03 is a first-in-class synthetic seven-amino-acid peptide derived from the caveolin-1 scaffolding domain (CSD), designed with a dual mechanism targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. The trial randomized 24 IPF participants 3:1 to LTI-03 5 mg/day (N=9), LTI-03 10 mg/day (N=9), or placebo (N=6) for 14 days. LTI-03 was well-tolerated with no treatment-related discontinuations, no severe TEAEs, and no spirometry-based airway obstruction; both doses significantly reduced interleukin-11 (p=0.0406 at 5 mg/day; p=0.044 at 10 mg/day) and thymic stromal lymphopoietin. The results were published the same day in Nature Communications (Philip Molyneaux MD, Imperial College London, presenting). LTI-03 has FDA Orphan Drug and Fast Track designations (Fast Track granted August 2026); the Phase 2 RENEW trial is enrolling across five countries with interim data anticipated H2 2026.